Once daily treatment with Denali's oral candidate DNL343 failed to reduce NfL levels in adults with ALS in the HEALEY trial.

Tris Pharma announced positive topline results from the ALLEVIATE-2 phase III clinical trial of investigational cebranopadol to treat moderate-to-severe acute pain after bunionectomy surgery. Axonal ...

Denali Therapeutics Inc.’s DNLI share price has dipped by 10.43%, which has investors questioning if this is right time to buy.

Nevertheless, the new disappointment with DNL343 is another major disappointment to ALS patients, who have limited drug ...

Denali Therapeutics' ALS drug DNL343 failed to show efficacy, leading to the discontinuation of the trial extension. Analysts now focus on its Hunter syndrome drug.

Denali Therapeutics’ amyotrophic lateral sclerosis (ALS) drug has racked up another clinical miss this year, leaving the ...

On March 5, 2025, Denali Therapeutics ( DNLI) Inc. provided an update that further analyses from Regimen G of the Phase 2/3 HEALEY ALS Platform Trial evaluating eIF2B agonist DNL343 in the treatment ...

Oppenheimer analyst Jay Olson lowered the firm’s price target on Denali Therapeutics (DNLI) to $42 from $50 and keeps an Outperform rating on ...

Suspects in the murder of Belfast man John George misled his family during efforts to find a body in Spain, BBC Spotlight finds. The former Spanish football federation president was found guilty ...

A former minister says dozens of families with babies born since a change to citizenship rules have asked him to help keep their children in New Zealand. The case of 18-year-old Daman Kumar - who ...

He talks about the importance of knowing your history. “Black History Month is about living history. It is not just recognizing some ancient African emperor, which we have," Dr. Miller-Jones ...